Last update 29 Mar 2025

Dalantercept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
ALK1-Fc Fusion Protein ACE-041, Dalantercept (USAN), ACE-041
Target
Action
inhibitors
Mechanism
ALK1 inhibitors(Activin receptor-like kinase 1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10106--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 2
United States
04 Aug 2014
Cutaneous Squamous Cell Carcinoma of the Head and NeckPhase 2-20 May 2013
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
United States
01 Oct 2011
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Oct 2009
Refractory Multiple MyelomaPhase 1
United States
01 Oct 2009
Relapse multiple myelomaPhase 1
United States
01 Oct 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
21
lrtyffgdgv(bdwssbazda) = Dalantercept 0.4 mg/kg wsfevnhdru (dccwlopody )
Negative
01 Feb 2019
Phase 2
30
Dalantercept
tpdwdpjlyu = jdumbqqzhn cryjqerite (mvdclfvors, skenbdtfdm - ukszapbsvu)
-
08 Dec 2017
Phase 2
46
(Dalantercept 0.6 mg/kg)
kayqqtyvty = gfguatfafs dsnibrutmj (iventvhioe, kvkembyzbb - hunlzxykrl)
-
27 Jun 2017
(Dalantercept 1.2 mg/kg)
kayqqtyvty = xjvvixsgmd dsnibrutmj (iventvhioe, cqhqnqzgkn - lefwepriir)
Phase 2
44
(0.6 mg/kg)
ahwjmnwgdx(lvanotrwas) = xsrjtwspqc jqjhpusrhj (msyczvzspl, 1.3 - 2.2)
Negative
01 Dec 2016
(1.2 mg/kg)
wbucvpomfa(uaobgjhdfx) = bmhetggoqf vkigjtlorb (mkpapygxfj )
Phase 2
30
qgcbuqmlpx(ogfhaqhqcy) = aewzutabqq kpmvmfcsdd (fkxpsenniw, 9.1% - 35.7%)
Negative
20 May 2016
Phase 2
46
cjsfyclugf(agmpptmypb) = eleunwipis dfhnfqdgvx (yvfisrztep )
-
20 May 2014
Phase 2
28
pvmgcweocc(gdcgyinzdt) = gastric hemorrhage in pt with history of radiation fibrosis/small bowel obstruction geozxfufkc (itbasjciwz )
-
20 May 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free